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Introduction
In patients with systemic lupus erythematosus (SLE),
hemorrhagic cystitis may be caused by the disease itself
or by the side effect of immunosuppressive agents such
as cyclophosphamide.1 Hemorrhagic cystitis is a com-
mon and sometimes life-threatening complication of
cyclophosphamide treatment. A 75% mortality rate has
been reported in patients with intractable refractory
cyclophosphamide-induced hemorrhagic cystitis.2
Several noninvasive methods have been used to treat
cyclophosphamide-induced hemorrhagic cystitis, but
none are effective enough to control intractable bleed-
ing.3 Hyperbaric oxygen therapy promotes capillary
angiogenesis and the healing process in damaged tis-
sue; it has been shown to be an effective treatment 
in the management of radiation-induced hemorrhagic
cystitis. Here, we report our experience with the use
of hyperbaric oxygen for the treatment of intractable
hemorrhagic cystitis in an SLE patient treated with
cyclophosphamide.
Case Report
A 40-year-old woman had been visiting our hospital
for gross hematuria on and off over the past 2 years,
with the problem being exacerbated in recent months.
Tracing her medical history, she had SLE under regular
treatment and follow-up at the rheumatology depart-
ment of another hospital. She had been on cyclophos-
phamide for 4 years for the control of her lupus.
Episodes of gross hematuria were noted for 2 years on
and off.
Cystoscopy was performed due to blood clot tam-
ponade, which revealed diffuse slough of urinary bladder
mucosa with active bleeding (Figure 1). Evacuation of
blood clots with cauterization of the bleeding points
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Successful treatment of cyclophosphamide-induced hemorrhagic cystitis
was done several times with poor response, and the
bleeding persisted. Blood transfusion of 4–6units every
week was necessary to maintain the patient’s hemoglo-
bin level above 10 g/dL. She refused formalin instilla-
tion due to fear of its possible complications.
She was referred to the hyperbaric oxygen center
and received 100% oxygen at 2.5 atmospheres chamber
pressure for 120 minutes daily for 28 days. The bleed-
ing diminished after the 28-day hyperbaric oxygen
treatment. Another 28-day course of hyperbaric oxygen
therapy was given. The bleeding ceased completely by
the end of the second course of hyperbaric oxygen ther-
apy. The patient tolerated the treatment well without
any complications. She did not experience any recurrence
of gross hematuria during the 6-month follow-up period.
Discussion
Cyclophosphamide is a powerful immunosuppressive
agent that is commonly used to treat neoplastic and
inflammatory diseases affecting various sites. Aggressive
immunosuppressive therapy with cyclophosphamide
has been proven to improve the outcome of major organ
preservation in SLE patients.4 However, hemorrhagic
cystitis is a common side effect of cyclophosphamide
treatment. Its urothelial toxicity is due to the urinary
excretion of acrolein, a cytotoxic metabolite of cyclo-
phosphamide that causes sloughing of bladder mucosa.
The urothelial damage has been associated with acute
and chronic hemorrhage. Hemorrhage usually occurs
during or immediately after cyclophosphamide treat-
ment, while delayed hemorrhage may occur in patients
on long-term therapy.5
The best way to treat cyclophosphamide cystitis 
is prevention. Hydration and the use of mesna 
(2-mercaptoethane sulfonate) have shown good results
for prevention. Hydration with vigorous diuresis may
dilute and wash out the urothelial-toxic metabolite to
minimize its damage. Mesna combines with acrolein
in the urine, so minimizing the side effects of acrolein
without compromising the efficacy of cyclophospha-
mide.3 Although mesna provides effective protection to
the urothelium, hemorrhagic cystitis still occurs in
10–40% of mesna-treated patients.6 Several therapeutic
options have been reported for the treatment of
cyclophosphamide-induced hemorrhagic cystitis. Blood
clot evacuation with electrocauterization of bleeding
points, intravesical instillation with alum, phenol and
prostaglandins have been used to control hemorrhage,
but these therapies often fail.7 Intravesical instillation
of formalin is an effective treatment modality to control
severe hemorrhagic cystitis. Formalin may occlude and
fix the telangiectatic tissue and small capillaries to control
bladder hemorrhage. However, formalin instillation has
significant risk of complications secondary to its fixative
properties. It may cause ureteral stenosis by vesicoureteral
reflux and bladder contracture due to fibrosis of the
bladder wall. Its potential damage to the urinary tract
means that it should be reserved as the last therapeutic
option when all other nonsurgical attempts have failed.1
Hyperbaric oxygen increases the oxygen gradient
between the damaged urothelium and the surrounding
tissue. It induces the healing of tissue damage, decreases
edema and promotes capillary angiogenesis by increas-
ing tissue oxygen levels 10- to 15-fold. Hyperbaric oxy-
gen has been reported to be an effective treatment
modality for patients with intractable radiation-induced
hemorrhagic cystitis.8,9 Neheman et al reported that
82% of patients treated with hyperbaric oxygen expe-
rienced an improvement or resolution of hematuria.10
Hyperbaric oxygen has been shown to be useful for
the prophylaxis and treatment of experimental
cyclophosphamide-induced hemorrhagic cystitis.3,11
There are also several case reports concerning the suc-
cessful use of hyperbaric oxygen for intractable hemor-
rhagic cystitis in patients undergoing cyclophosphamide
treatment for malignant disease.7,12
In SLE patients, hemorrhagic cystitis may be caused
by the disease itself or be the side effect of immuno-
suppressive agents such as cyclophosphamide. In our
case, hyperbaric oxygen for the treatment of refractory
hemorrhagic cystitis led to an excellent result without
any complications. To our knowledge, this is the first
case report on the use of hyperbaric oxygen therapy for
the treatment of cyclophosphamide-induced hemor-
rhagic cystitis in an SLE patient.
Figure 1. Cystoscopy shows ablation of bladder mucosa with active
bleeding.
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